作为抗炎剂的莫卢金衍生物:设计,合成和NF-κB抑制
Yuan-Liang Gao1, Ming-Yue Li1, Da-Yuan Wang1
1Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, College of Pharmacy, Yanbian University, Yanji, China.
Chemical biology & drug design
|December 20, 2024
概括
研究人员开发了新型的软衍生物来向炎症. 化合物5k通过抑制核因子kB (NF-kB) 信号传递显示出显著的抗炎作用,显示出作为治疗剂的希望.
科学领域:
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 核因子 κB (NF-κB) 是一个关键的转录因子,调节炎症和免疫反应.
- 抑制NF-κB信号通路是治疗炎症的关键策略.
- 研究了mollugin衍生物的潜力,以调节NF-κB活动.
研究的目的:
- 设计和合成新型的软藻衍生物.
- 通过评估它们抑制NF-κB转录的能力来评估这些衍生物的抗炎活性.
- 为了研究有前途的化合物的作用机制和药理动力学特性.
主要方法:
- 合成了27种软藻衍生物.
- 在体外评估针对NF-κB转录的抗炎活性.
- 在体内评估通过腹膜内给药5k化合物的疗效.
- 作用研究的机制,包括p65蛋白表达分析.
- 对药物动力学特性进行ADMET预测.
- 分子对接模拟以将结构与活动相关联.
主要成果:
- 大多数合成的软蛋白衍生物显示出强大的抗炎活性.
- 化合物5k表现出最高的疗效 (81.77%的抑制),超过了摩尔古因,易布洛芬和梅萨拉.
- 发现5k化合物降低NF-κB表达的调节,可能通过抑制LPS诱导的p65蛋白表达.
- ADMET的预测表明,对于5h和5k化合物的药理学概况有利.
- 分子对接提供了对结构-活动关系的见解.
结论:
- 新型软藻衍生物具有显著的抗炎功能.
- 化合物5k是一种高度强大的NF-κB信号传递的抑制剂.
- 化合物5h和5k在进一步开发抗炎药物方面表现出有希望的特性.
相关概念视频
02:26NF-κB-dependent Signaling Pathway
7.2K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.2K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
115
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
115
02:04Co-activators and Co-repressors
7.3K
Gene transcription is regulated by the synergistic action of several proteins that form a complex at a gene regulatory site. This is observed in eukaryotes, where the regulation of gene expression is a complex process. Regulatory proteins in eukaryotes can broadly be classified into two types – regulators that bind directly to specific DNA sequences and co-regulators that associate with regulatory proteins but cannot directly bind to the DNA. These co-regulators are further divided into...
7.3K
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
347
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
347
01:31Transducer Mechanism: Nuclear Receptors
1.3K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
1.3K
01:29Drugs for Treatment of Ulcerative Colitis in IBD
119
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
119